Andrew Armstrong
@AarmstrongDuke
Followers
2K
Following
1K
Media
106
Statuses
897
Professor of Medicine, Surgery, Pharmacology and Cancer Biology, Duke Cancer Institute, Durham NC
Chapel Hill, NC
Joined October 2016
Adjuvant nivo remains positive for DFS HR-0.73 but still not +ve for OS 0.83 in operable UC #ESMO25 . Enrichment occurred the ctDNA +ves (DFS HR=0.3 & OS HR=0.44) as in IMvigor010. The ctDNA negatives were at much lower risk didn’t seem to benefit from IO (HR-DFS 0.99, OS 0.87)
3
44
105
0
2
5
#POTOMAC implementation would require a market shift in multidisciplinary care with med onc playing a larger role in treatment naive #NMIBC for systemic therapy, a disease mostly treated by community urologists. DFS can be a meaningful marker here but requires discussion. #ESMO25
Durvalumab in combination with BCG for BCG-naïve high-risk #NMIBC: Final analysis of the phase 3, open-label, randomized #POTOMAC trial. Presentation by @mdesantis234 @ChariteBerlin. #ESMO25 written coverage by @zklaassen_md @GACancerCenter > https://t.co/s05aRUNwMi
@myESMO
0
1
5
Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science
6
88
169
About to go to Berlin and attend #ESMO25 — fantastic line up in GU cancers — 7 of these top picks are first readouts of phase 3 trials! Thanks @OncoAlert for compiling and look forward to seeing you @myESMO #ESMOAmbassadors!
The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System
0
16
47
Remember LRP1b? Predicts IO benefits across solid tumors in @jitcancer
https://t.co/pTOp5ETfDW Now validated in Checkmate 026 (NSCLC) with nivo and the national @FoundationATCG database: https://t.co/UPcNFv5ffu
@DukeGUCancer @DukeCancer @bmsnews
aacrjournals.org
Abstract. Purpose: Low-density lipoprotein receptor-related protein 1b (LRP1b) is a cell surface receptor, commonly altered in many cancers and associated with improved responses, progression free...
0
3
6
How about the HR for non BRCAm?
🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 https://t.co/BYx1L9i7GC
@PCFnews @OncoAlert @urotoday
0
2
13
Interested in targeting the prostate cancer surfaceome? See our review out today in @pcan_journal led by two outstanding GU fellows Bilal Ashraf and Jane McKenzie from @DukeCancer @DukeGUCancer and @PeterMacCC
nature.com
Prostate Cancer and Prostatic Diseases - Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer
1
3
23
16,138 Chinese physicians joined virtually for the “Academic Exchange on Frontier Diagnosis and Treatment of Urological Tumors” webinar. A heartfelt thank you to all the excellent speakers! @AarmstrongDuke @DukeGUCancer @PCFnews @DukeCancer @MUHospital @Macquarie_Uni
0
2
5
SPARC: The Standardised Prostate-specific Membrane Antigen PET-CT Analysis and Reporting Consensus Open access: https://t.co/eRV0qqREB6
@Uroweb
@EUplatinum Bringing together all the PSMA guidelines into one modern consensus. Please use a template when reporting PSMA PET/CT !
2
35
104
Biparametric vs Multiparametric MRI for Prostate Cancer DiagnosisThe PRIME Diagnostic Clinical Trial https://t.co/HOZdfhhsWT Investigators compared biparametric MRI (without contrast) to standard multiparametric MRI for diagnosing clinically significant #ProstateCancer in
0
19
30
CHAARTED Ten-year survival rates: Time to re-think de-escalation! Achieving a PSA nadir below 0.2 ng/mL within 6 months is a strong predictor of overall survival, supporting its role in response-adapted de-escalation strategies. @Annals_Oncology @myESMO @eaonc @ERPlimackMD
3
81
221
IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last https://t.co/dPqlvr2rnV
9
114
285
A new model for mCRPC that adds ctDNA-based genomic alterations to clinical data improves overall survival prediction by ~30%. AR, PTEN, TP53, MYC among key drivers. A step closer to precision trials. #ProstateCancer #Oncology
@mishabeltran @EAntonarakis @MattGalsky
1
20
58
Can anyone top the Halabi model for predicting survival in mCRPC? Yes! Dr Halabi does it again! See our ctDNA based clinical-genetic model in first line ARPI treatment out today in @EUplatinum: https://t.co/OOeFavZgG8
@scottdehm @DukeGUCancer @DukeCancer @PCFnews
0
4
15
Thank you Terry and Joe for a great conversation on @NPR @PeoplesPharmacy to talk about prostate cancer: https://t.co/pIQ8OFygEF
@DukeGUCancer @PCFnews @DukeCancer
peoplespharmacy.com
New advances mean that more men than ever before can overcome prostate cancer. Treatments can extend life and improve quality of life.
2
2
10
Findings from a recent MAIC analysis suggest that enzalutamide plus ADT may prolong rPFS and time to castration resistance compared with darolutamide plus ADT in patients with mHSPC. #pcsm @AarmstrongDuke @DukeUrology
https://t.co/L8fV2nkuZU
urologytimes.com
Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.
0
2
9
Unfortunately my R01 scored 7% will not get funded. 😭Due to the new rule to use at least half of the remaining FY25 budget for upfront payment for future, NCI R01 payline dropped to 4% last week.
5
4
24
Choosing an ARPI in the mHSPC setting is a highly individualized decision. Our recent MAIC analysis compares ARCHES and ARANOTE similar cohorts for efficacy of enza vs daro for improving rPFS. Interesting results! https://t.co/t6fEkyWrOG
@DukeGUCancer @AzadOncology @DukeCancer
tandfonline.com
To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus darolutamide + ADT for treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) using a ma...
0
6
20